Google
OGN Stock Analysis — ORGANON & CO (Healthcare >> Drug Manufacturers - General)
OGN FAQ
What is OGN's P/E ratio?
ORGANON & CO (OGN) currently trades at a P/E ratio of 7.89.
What is OGN's ROE?
ORGANON & CO reports a Return on Equity (ROE) of 27.24%.
What is OGN's dividend yield?
ORGANON & CO offers a dividend yield of 0.59%.
What is OGN's Quality Score?
Our AI rates OGN's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy OGN?
Our AI Timing Score for OGN is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does OGN belong to?
ORGANON & CO is classified under the Healthcare >> Drug Manufacturers - General sector on the NYSE exchange
OGN AI Analysis Summary
Our AI summary for OGN: ORGANON & CO (NYSE), Healthcare >> Drug Manufacturers - General sector. The stock currently trades at a P/E of 7.89, ROE of 27.24%, a dividend yield of 0.59%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 13.55
Price
0.00
(0.00%)
Day Change
|
|
|---|
OGN, the overall quality is not good ( Quality = 38) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
51% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
1460
|
| Magic Formula Rank by ROE |
1460
|
| Magic Formula Rank by ROIC |
657
|
| Price | 13.55 |
| PBV / Sector |
3.94 / 2.68
|
| Earning Per Share | 0.94 |
| PE / Sector |
7.89 / 27.65
GREAT
|
| PEG or PE/Growth / Sector |
-0.28 / 0.28
|
| Average 1M Daily Value |
30.45 M
GREAT
|
| Average 1W Daily Value |
29.21 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
58% |
| Return to Investors |
|
41% |
| Registration Details |
| Analyze Date | 2026-08-01 08:00:16 |
| Symbol | OGN |
| Name | ORGANON & CO |
| Sector | Healthcare >> Drug Manufacturers - General |
| Market | NYSE |
| Listed Shares | 262.61 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 3,558.36 / 256,404.20 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 30 Hudson Street, Jersey City, NJ, United States, 07302
Phone: 551 430 6900
Website: https://www.organon.com
Employees: 10,000
Description: Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Drug Manufacturers - General
Click a bubble to view stock details · Bubble size represents market capitalization share
